Neurocrine biosciences and idorsia amend option agreement to license novel treatment for rare pediatric epilepsy

Neurocrine biosciences : :neurocrine biosciences and idorsia amend option agreement to license novel treatment for rare pediatric epilepsy.neurocrine

NBIX Ratings Summary

NBIX Quant Ranking